33662-26-9

Basic information

• Product Name: BOC-THR-OBZL
• Synonyms: BOC-THR-OBZL;Boc-L-Thr-OBzl;Boc-L-threonine benzyl ester;N-tert-Butoxycarbonyl-L-threonine benzyl ester;L-Threonine, N-[(1,1-dimethylethoxy)carbonyl]-, phenylmethyl ester;(Tert-Butoxy)Carbonyl Thr-OBzl
• CAS NO: 33662-26-9
• Molecular Formula: C₁₆H₂₃NO₅
• Molecular Weight: 309.36
• Mol File: 33662-26-9.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BOC-THR-OBZL(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-THR-OBZL(33662-26-9)
• EPA Substance Registry System: BOC-THR-OBZL(33662-26-9)

Safety Data

• Hazardous Substances Data: 33662-26-9(Hazardous Substances Data)

Usage

Description

BOC-THR-OBZL, also known as Boc-Thr-Obzl, is a synthetic peptide compound that plays a significant role in the development of pharmaceuticals targeting specific enzymes. It is characterized by its ability to inhibit certain enzymes, making it a valuable component in the treatment of various medical conditions.

Uses

Used in Pharmaceutical Industry:
BOC-THR-OBZL is used as a precursor in the synthesis of substituted oxopyridine derivatives, which serve as inhibitors for factor XIa and plasma kallikrein. These inhibitors are crucial in the treatment of thrombotic or thromboembolic diseases, as they help regulate the coagulation process and prevent the formation of blood clots.
In the development of these inhibitors, BOC-THR-OBZL plays a vital role in providing a stable and specific structure that can effectively target the enzymes responsible for the clotting process. This targeted approach allows for more effective treatment options with fewer side effects, making it a valuable asset in the pharmaceutical industry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-39-0 benzyl bromide 
• 13564-70-0 Boc-L-allo threonine dicyclohexylamine 
• 2592-18-9 Boc-Thr-OH 
• 100-44-7 benzyl chloride 
• 2592-18-9 tert-Butoxycarbonylamino-3-hydroxy-butyric acid 
• 33640-67-4 (2S,3R)-threonine benzyl ester 
• 100-46-9 benzylamine 
• 201274-07-9 L-threonine benzyl ester oxalate salt 

Downstream Products

• 66592-96-9 (2S,3R)-3-[2-(4-Benzyloxycarbonylamino-butyryloxy)-acetoxy]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 140422-53-3 2-tert-Butoxycarbonylamino-3-methanesulfonyloxy-butyric acid benzyl ester 
• 13564-70-0 Boc-L-allo threonine dicyclohexylamine 
• 33640-67-4 (2S,3R)-threonine benzyl ester 
• 174536-89-1 (2S,3R)-3-Acetoxy-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 178271-69-7 (2S,3R)-2-tert-Butoxycarbonylamino-3-((2R,3S,4R,5R,6S)-3,4,5-tris-benzyloxy-6-methyl-tetrahydro-pyran-2-yloxy)-butyric acid benzyl ester 
• 193140-91-9 (2S,3R)-2-tert-Butoxycarbonylamino-3-[(2R,3R,4R,5S,6R)-4,5-diacetoxy-6-acetoxymethyl-3-(4,5,6,7-tetrachloro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-tetrahydro-pyran-2-yloxy]-butyric acid benzyl ester 
• 193140-98-6 (2S,3R)-2-tert-Butoxycarbonylamino-3-((2R,3R,4R,5S,6R)-4,5-diacetoxy-6-acetoxymethyl-3-diacetylamino-tetrahydro-pyran-2-yloxy)-butyric acid benzyl ester 
• 192211-87-3 (2S,3R)-3-[(S)-2-(Acetyl-methyl-amino)-3-(4-methoxy-phenyl)-propionyloxy]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 140422-46-4 benzyl (Z)-2-((tert-butoxycarbonyl)amino)but-2-enoate 
• 221198-05-6 N-Boc-Thr[N-Fmoc-D-Ala]-OBn 
• 395063-31-7 (2S,3R)-2-tert-butoxycarbonylamino-3-(toluene-4-sulfonyloxy)-butyric acid benzyl ester 
• 909115-17-9 O-[(N-benzyloxycarbonyl)alanyl]-N-(tert-butyloxycarbonyl)-threonine benzyl ester 
• 909115-19-1 O-[(N-9-fluorenylmethyloxycarbonyl)alanyl]-N-(tert-butyloxycarbonyl)-threonine benzylester 

Relevant articles and documents

METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES

Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

Silver-Promoted Direct Phosphorylation of Bulky C(sp2)-H Bond to Build Fully Substituted β-Phosphonodehydroamino Acids

A general and practical cross-dehydrogenative coupling protocol between readily available trisubstituted α,β-dehydro α-amino carboxylic esters and H-phosphites is described. This C(sp2)-H phosphorylation reaction proceeds with absolute Z-selectivity promoted by silver salt in a radical relay manner. The bulky tetrasubstituted β-phosphonodehydroamino acids were obtained in grams and added new modules to the toolkit for peptide modifications.

General Fmoc-Based Solid-Phase Synthesis of Complex Depsipeptides Circumventing Problematic Fmoc Removal

Development of an Fmoc-based solid-phase depsipeptide methodology has been hampered by base-promoted fragmentation and diketoperazine formation upon Fmoc group elimination. Such a strategy would be a useful tool given the number of commercially available Fmoc-protected residues. Herein we report that the addition of small percentages of organic acids to the Fmoc-removal cocktail proves effective to circumvent these drawbacks and most importantly, allowed the development of an exclusively solid-phase stepwise methodology to prepare a highly complex depsipeptide with multiple and consecutive esters bonds. Alongside, the optimal protecting group scheme for residue incorporation, which is not as straightforward as it is for traditional peptide synthesis, was explored. The developed stepwise strategy proved effective for the synthesis of a highly complex cyclodepsipeptide, being comparable to the yields obtained when using traditional combined chemistry approaches.